Public procurement notice: Contract Notice
Published: 2020-03-05
Buyer: Swansea University
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33100000 | 38000000 | 38434540 | 38510000 | 39162000
Estimated value: 280000 GBP
Submission deadline: 2020-04-02
Award criteria: The most economic tender
EU fund: ERDF

Technical requirements: The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for:
The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments
For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation.
The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for:
The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments
For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation.
Funding may be from different sources including Welsh Govt, UK Govt, European Investment Bank Loan or ERDFund through the Welsh Govt.
The funding for this purchase covers only the lease not purchase of the equipment. Therefore we are seeking a supplier who can lease the equipment detailed within the tender specification for the duration of the CEAT project.
As detailed within the tender specification for the lease not purchase of the equipment detailed for the project duration.
The funding for this equipment is for the lease not purchase of the detailed equipment, for the duration of the CEAT project up to 31 October 2021
Note: the authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at https://www.sell2wales.gov.wales/search/search_switch.aspx?ID=99500


Award value: 280000